PubMed Health⌕ Search

Biomedical subjects

G Iosilevsky

Publications and source records attributed to G Iosilevsky.

23 records · Page 2Linked to original sources

Human lung tumors: SPECT quantitation of differences in Co-57 bleomycin uptake.

A newly developed single photon emission computed tomography (SPECT) method was used to measure noninvasively the concentration of labeled drugs in human lung tumors. The validity of the method was established by the high correlation (r = .92) between in vivo SPECT measurement of the concentration of glucoheptonate labeled with technetium-99m and in vitro measurement of the concentration of the drug in specimens of nine of the same tumors obtained at surgery. The in vivo concentration of intravenously injected bleomycin labeled with cobalt-57 was measured over time in 14 human lung tumors. Significant differences were found in the uptake of bleomycin by the tumors, even those with the same histologic characteristics, when the concentration over time, the tumor/blood ratio at 30 minutes, and the tumor cumulative concentration were measured in vivo. Since the drug concentration in the blood was not related to the concentration in the tumor (r = .54), uptake of chemotherapeutic drugs should be measured in each patient individually.

Adenocarcinoma↗

Monitoring of 57Co-bleomycin delivery to brain metastases and their tumors of origin.

The concentration of cobalt-57 (57Co)-labeled bleomycin delivered to three brain metastases and to their tumors of origin in the lungs was measured using a single-photon emission computerized tomography technique. In two brain metastases the 57Co-bleomycin concentration measured at different times after the intravenous injection was significantly lower than that in the originating lung tumors (p less than 0.01 and p less than 0.001). In these two patients, the tumor cumulative concentration (TCC) of drug in the brain neoplasm compared to the lung carcinoma was 12.92 versus 15.12 and 10.30 versus 19.74 micrograms/cc/min. In the third patient there was no significant difference in drug concentration between the tumor in the brain and in the lung (TCC 16.02 vs. 15.09 micrograms/cc/min). There was a significant difference in the drug TCC between the three brain metastases: the difference between the lowest and highest concentrations was more than 50% (10.3 vs. 16.02 micrograms/cc/min). When the concentration in the tumor over time (CT(t)) of the 57Co-bleomycin was compared in the brain and lung tumors, a good correlation was found in each of the three cases (r = 0.93, 0.99, and 0.97). This suggests that the difference in drug uptake between brain metastases and their originating lung tumor is a quantitative rather than a qualitative phenomenon. The results show that the amount of drug to which brain metastases are exposed varies and may be very low in some tumors; therefore, effectiveness of drug delivery may play a role in the nonresponsiveness of brain metastases to treatment.

Bleomycin↗

Human sarcoma-associated murine monoclonal antibody labeled with indium-111, gallium-67, and iodine-125.

Monoclonal antibody (MAb) 23H7 is a hybridoma-derived IgG that is generated following fusion of mouse myeloma cell line P3U1 and spleen cells from BALB/c mice hyperimmunized with a human fibrosarcoma. It detects a mesenchymal antigen of 23KD expressed on human sarcoma tissues and other neoplasms, including myeloid leukemias, but it rarely binds to normal tissues. The MAb 23H7 was labeled with 67Ga and 111In using the bifunctional ligand method. The 67Ga was chelated to the MAb via desferrioxamine B, while 111In was chelated via the cyclic anhydride of diethylenetriamine pentaacetic acid. Higher specific activity was obtained with 67Ga than with 111In (4.5 and 2 muCi/microgram, respectively); both gave stable complexes. When 23H7 was labeled with 125I, considerable breakdown was observed. This, together with the physical shortcomings of this isotope, emphasizes the advantages of labeling with 111In and 67Ga. The rapid blood clearance of the labeled sarcoma-associated MAb may be beneficial for early tumor uptake and for imaging shortly after injection.

Animals↗

Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy.

Uptake of 67Ga and [3H]DG after radiation and chemical therapy was measured in a tumor model. Uptake of both agents in treated viable tumors did not differ significantly from the uptake in viable control tumors. However, when tumors showed, after therapy, partial or complete fibrosis, there was a significant decrease in uptake. Viable tumors showed the whole range of weight response to therapy, and the mean weight of viable tumors did not differ significantly from the mean weight of partially viable tumors. The results indicate that, in the tumor model used in this study, 67Ga and [3H]DG could be used to monitor tumor response to therapy. Tumor weight was not a reliable indicator of the effect of therapy at early stages when the tumor is partially viable.

Animals↗

Scintigraphic assessment of technetium 99m-diphosphonate uptake, vascularity and vessel permeability in human bone tumours.

Differences in the rate of uptake of 99Tcm-diphosphonate were found in 20 human bone tumours investigated. As some tumours have a slow rate of uptake it is suggested that the time used for routine scintigraphy at 3 hours is not always optimal and a further study should be performed in some cases. Various degrees of tumour vascularity and vessel permeability were found. The rate of diphosphonate uptake correlates with the vascularity, while it does not correlate with permeability which is generally increased as compared to normal bone.

Bone Neoplasms↗